Epstein–Barr Virus (HHV-4) Infections – Pipeline Review, H1 2017

Global Markets Direct’s, ‘EpsteinBarr Virus (HHV-4) Infections – Pipeline Review, H1 2017’, provides an overview of the EpsteinBarr Virus (HHV-4) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for EpsteinBarr Virus (HHV-4) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for EpsteinBarr Virus (HHV-4) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of EpsteinBarr Virus (HHV-4) Infections

– The report reviews pipeline therapeutics for EpsteinBarr Virus (HHV-4) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved EpsteinBarr Virus (HHV-4) Infections therapeutics and enlists all their major and minor projects

– The report assesses EpsteinBarr Virus (HHV-4) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for EpsteinBarr Virus (HHV-4) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for EpsteinBarr Virus (HHV-4) Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding EpsteinBarr Virus (HHV-4) Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Arno Therapeutics Inc

Cell Medica Ltd

Epiphany Biosciences Inc

Genocea Biosciences Inc

Omeros Corp

Savoy Pharmaceuticals Inc

Theravectys SA

Viracta Therapeutics Inc

Vironika LLC

ViroStatics srl

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

EpsteinBarr Virus (HHV-4) Infections Overview

EpsteinBarr Virus (HHV-4) Infections Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

EpsteinBarr Virus (HHV-4) Infections Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

EpsteinBarr Virus (HHV-4) Infections Companies Involved in Therapeutics Development

Arno Therapeutics Inc

Cell Medica Ltd

Epiphany Biosciences Inc

Genocea Biosciences Inc

Omeros Corp

Savoy Pharmaceuticals Inc

Theravectys SA

Viracta Therapeutics Inc

Vironika LLC

ViroStatics srl

EpsteinBarr Virus (HHV-4) Infections Drug Profiles

AR-12 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baltaleucel-T Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for EBV Associated Malignancies Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for EBV Associated PTLD Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Infectious Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Systemic Lupus Erythematosus, Epstein-Barr Viral Infections and Multiple Sclerosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Viral Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Viral Infections Post-HSCT Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target Calcineurin A for EBV Associated Post Transplant B-Cell Lymphoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target LMP1, LMP2, BARF-1 and EBNA1 for EBV Associated Cancers and Infection Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBViNT Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epstein-Barr virus (virus like particle) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epstein-Barr virus vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEN-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MVA vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EBNA1 for Epstein-Barr Virus Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valomaciclovir stearate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viralym-M Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viroprev Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VRx-3996 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EpsteinBarr Virus (HHV-4) Infections Dormant Projects

EpsteinBarr Virus (HHV-4) Infections Product Development Milestones

Featured News & Press Releases

Dec 01, 2016: ViraCyte Announces Oral Presentations on Viralym-M Clinical Trial Results at the 58th American Society of Hematology Annual Meeting

Aug 18, 2016: Vironika Secures Phase I SBIR Funding From NIH To Develop Inhibitors For EBV Lytic Reactivation

Jun 02, 2014: Vironika Receives Phase II SBIR Grant From NIH To Continue The Development Of EBV Latency Inhibitors

Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for EpsteinBarr Virus (HHV-4) Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by Arno Therapeutics Inc, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by Cell Medica Ltd, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by Epiphany Biosciences Inc, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by Genocea Biosciences Inc, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by Omeros Corp, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by Savoy Pharmaceuticals Inc, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by Theravectys SA, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by Viracta Therapeutics Inc, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by Vironika LLC, H1 2017

EpsteinBarr Virus (HHV-4) Infections Pipeline by ViroStatics srl, H1 2017

EpsteinBarr Virus (HHV-4) Infections Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for EpsteinBarr Virus (HHV-4) Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports